# US 2020/0390731 A1 · Manipulation of the retinoic acid signaling pathway

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390731 A1
- Document ID: US20200390731A1
- Status: Published application
- Kind: A1
- Application number: 16/763,180
- Filed: 2018-11-16
- Published: 2020-12-17
- Earliest claimed: 2017-11-17
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Richard H. Kramer; Michel Telias; Bristol Layne Denlinger; Zachary John Helft
- Web page: https://patentgrep.com/patent/US20200390731A1

## CPC

- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 27/02: Ophthalmic agents
- C07K 14/70567: {Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/86: Viral vectors
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- C07K 2319/41: containing a Myc-tag
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein, inter alia, are compositions and methods for modulating the retinoic acid receptor signaling pathway and treating vision degeneration.

## Claims

### Claim 1

A method of treating vision degeneration, said method comprising administering to a subject in need thereof an effective amount of a retinoic acid receptor inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the retinoic acid receptor inhibitor is an RAR antagonist.

### Claim 3 (depends on 2)

The method of claim 2, wherein the RAR antagonist inhibits the binding of a nuclear receptor coactivator to the retinoic acid receptor.

### Claim 4 (depends on 1)

The method of claim 1, wherein the retinoic acid receptor inhibitor is an RAR inverse agonist.

### Claim 5 (depends on 4)

The method of claim 4, wherein the RAR inverse agonist increases the binding of a nuclear receptor corepressor to the retinoic acid receptor.

### Claim 6 (depends on 1)

The method of claim 1, wherein light sensitivity of retinal ganglion cells in the subject is increased.

### Claim 7 (depends on 1)

The method of claim 1, wherein hyperexcitability of retinal ganglion cells in the subject is inhibited.

### Claim 8 (depends on 1)

The method of claim 1, wherein increases in the number, activity, or cellular distribution of hyperpolarization-activated cyclic nucleotide-gated channel in retinal ganglion cells are reduced.

### Claim 9 (depends on 1)

The method of claim 1, wherein the vision degeneration is associated with retinitis pigmentosa, age-related macular degeneration, cone dystrophy, rod-cone dystrophy, Leber's congenital amarurosis, Usher's syndrome, Bardet-Biedl-syndrome, or Stargardt disease.

### Claim 10

A method of inhibiting the activity of a retinoic acid receptor in a subject in need thereof, comprising contacting the retinoic acid receptor with a retinoic acid receptor inhibitor.

### Claim 11 (depends on 10)

The method of claim 10, wherein the retinoic acid receptor inhibitor is an RAR antagonist.

### Claim 12 (depends on 11)

The method of claim 11, wherein the RAR antagonist inhibits the binding of a nuclear receptor coactivator to the retinoic acid receptor.

### Claim 13 (depends on 10)

The method of claim 10, wherein the retinoic acid receptor inhibitor is an RAR inverse agonist.

### Claim 14 (depends on 13)

The method of claim 13, wherein the RAR inverse agonist increases the binding of a nuclear receptor corepressor to the retinoic acid receptor.

### Claim 15 (depends on 10)

The method of claim 10, wherein the retinoic acid receptor contacts a retinoid x receptor.

### Claim 16 (depends on 15)

The method of claim 15, wherein the retinoic acid receptor inhibitor contacts the retinoid x receptor.

### Claim 17 (depends on 1)

The method of claim 1, wherein the retinoic acid receptor is RARα.

### Claim 18 (depends on 1)

The method of claim 1, wherein the retinoic acid receptor inhibitor has the formula:
wherein
L1 is a bond, —S(O)2—, —NH—, —O—, —S—, —C(O)—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(O)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
L2 is —S(O)2—, —NH—, —O—, —S—, —C(O)—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(O)NH—, —C(O)O—, —OC(O)—, —C(S)—, —C(S)NH—, —NHC(S)—, —NHC(S)NH—, —NHC(S)NH—, —C(S)O—, —OC(S)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
R1 is halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2 and R3 are each independently hydrogen, or substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;
R4 and R5 are each independently halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
z4 is an integer from 0 to 3; and
z5 is an integer from 0 to 4.

### Claim 19 (depends on 18)

The method of claim 18, wherein L2 is

### Claim 20 (depends on 18)

The method of claim 18, wherein -L1-R1— has the formula:

### Claim 21 (depends on 1)

The method of claim 1, wherein the retinoic acid receptor inhibitor is

### Claim 22 (depends on 21)

The method of claim 21, wherein the retinoic acid receptor inhibitor is

### Claim 23 (depends on 1)

The method of claim 1, wherein the retinoic acid receptor inhibitor comprises a nucleic acid.

### Claim 24 (depends on 23)

The method of claim 23, wherein the retinoic acid receptor inhibitor is a nucleic acid.

### Claim 25 (depends on 1)

The method of claim 1, wherein the retinoic acid receptor inhibitor comprises a gene modulating reagent.

### Claim 26 (depends on 25)

The method of claim 25, wherein the gene modulating reagent is a gene editing reagent or a gene modulating nucleic acid.

### Claim 27 (depends on 26)

The method of claim 26, wherein the gene editing reagent is a CRISPR complex, a TAL effector nuclease, a zinc-finger nuclease, a meganuclease, or a homing endonuclease.

### Claim 28 (depends on 27)

The method of claim 27, wherein the CRISPR complex comprises a guide RNA and a Cas9 nuclease.

### Claim 29 (depends on 28)

The method of claim 28, wherein the guide RNA comprises a nucleic acid sequence at least 80% identical to an RNA sequence of a retinoic acid receptor or a fragment thereof or a complement thereof.

### Claim 30 (depends on 28)

The method of claim 28, wherein the guide RNA comprises a nucleic acid sequence identical to an RNA sequence of a retinoic acid receptor or a fragment thereof, or a complement thereof.

### Claim 31 (depends on 29)

The method of claim 29, wherein the guide RNA comprises a nucleic acid sequence from 10 to 30 nucleotides in length.

### Claim 32 (depends on 28)

The method of claim 28, wherein the guide RNA comprises a nucleic acid sequence at least 80% identical to an RNA sequence of a retinoic acid receptor or a fragment thereof, or a complement thereof, or an RNA sequence or a fragment thereof, or a complement thereof corresponding to a nucleic acid sequence upstream or downstream of the retinoic acid receptor transcription start site.

### Claim 33 (depends on 28)

The method of claim 28, wherein the guide RNA comprises a nucleic acid sequence from 10 to 30 nucleotides in length and at least 80% identical to an RNA sequence of a retinoic acid receptor or a fragment thereof, or a complement thereof, or an RNA sequence or a fragment thereof, or a complement thereof corresponding to a nucleic acid sequence upstream or downstream of the retinoic acid receptor transcription start site.

### Claim 34 (depends on 26)

The method of claim 26, wherein the gene modulating nucleic acid is an antisense nucleic acid or an siRNA.

### Claim 35 (depends on 34)

The method of claim 34, wherein the antisense nucleic acid comprises a nucleic acid sequence at least 80% identical to a nucleic acid sequence complementary to an RNA sequence of a retinoic acid receptor or a fragment thereof.

### Claim 36 (depends on 34)

The method of claim 34, wherein the antisense nucleic acid comprises a nucleic acid sequence complementary to an RNA sequence of a retinoic acid receptor or a fragment thereof.

### Claim 37 (depends on 34)

The method of claim 34, wherein the antisense nucleic acid comprises a nucleic acid sequence at least 80% identical to a nucleic acid sequence complementary to an RNA sequence of a retinoic acid receptor or a fragment thereof, or a nucleic acid sequence or a fragment thereof upstream or downstream of the retinoic acid receptor transcription start site.

### Claim 38 (depends on 35)

The method of claim 35, wherein the antisense nucleic acid comprises a nucleic acid sequence from 10 to 50 nucleotides in length.

### Claim 39 (depends on 34)

The method of claim 34, wherein the antisense nucleic acid comprises a nucleic acid sequence from 10 to 50 nucleotides in length and at least 80% identical to a nucleic acid sequence complementary to an RNA sequence of a retinoic acid receptor or a fragment thereof, or a nucleic acid sequence or a fragment thereof upstream or downstream of the retinoic acid receptor transcription start site.

### Claim 40 (depends on 34)

The method of claim 34, wherein the siRNA comprises a nucleic acid sequence at least 80% identical to a nucleic acid sequence complementary to an RNA sequence of a retinoic acid receptor or a fragment thereof.

### Claim 41 (depends on 34)

The method of claim 34, wherein the siRNA comprises a nucleic acid sequence identical to an RNA sequence complementary to an RNA sequence of a retinoic acid receptor or a fragment thereof.

### Claim 42 (depends on 34)

The method of claim 34, wherein the siRNA comprises a nucleic acid sequence at least 80% identical to a nucleic acid sequence complementary to an RNA sequence of a retinoic acid receptor or a fragment thereof, or a nucleic acid sequence or a fragment thereof upstream or downstream of the retinoic acid receptor transcription start site.

### Claim 43 (depends on 40)

The method of claim 40, wherein the siRNA comprises a nucleic acid sequence from 20 to 30 nucleotides in length.

### Claim 44 (depends on 34)

The method of claim 34, wherein the siRNA comprises a nucleic acid sequence from 20 to 30 nucleotides in length and at least 80% identical to a nucleic acid sequence complementary to an RNA sequence of a retinoic acid receptor or a fragment thereof, or a nucleic acid sequence or a fragment thereof upstream or downstream of the retinoic acid receptor transcription start site.

### Claim 45 (depends on 23)

The method of claim 23, wherein the retinoic acid receptor inhibitor comprises an expression vector.

### Claim 46 (depends on 45)

The method of claim 45, wherein the expression vector is a viral vector.

### Claim 47 (depends on 45)

The method of claim 45, wherein the expression vector is an adenovirus vector, adeno-associated virus vector, or a lentiviral vector.

### Claim 48 (depends on 45)

The method of claim 45, wherein the expression vector is capable of expressing a dominant negative retinoic acid receptor protein.

### Claim 49 (depends on 48)

The method of claim 48, wherein the dominant negative retinoic acid receptor protein is a truncated retinoic acid receptor compared to the wildtype retinoic acid receptor protein.

### Claim 50

A method of treating vision degeneration, said method comprising administering to a subject in need thereof an effective amount of an inhibitor of the level of retinoic acid in the subject.

### Claim 51 (depends on 50)

The method of claim 50, wherein the inhibitor is a retinaldehyde dehydrogenase inhibitor.

### Claim 52 (depends on 51)

The method of claim 51, wherein the retinaldehyde dehydrogenase inhibitor is diethylaminobenzaldehyde, citral, or disulfiram.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of one of claims 1 to 52, wherein the retinoic acid receptor inhibitor is administered topically to the eye.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of one of claims 1 to 52, wherein the retinoic acid receptor inhibitor is administered by intraocular, subconjunctival, intravitreal, retrobulbar, or intracameral administration.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of one of claims 1 to 52, wherein the retinoic acid receptor inhibitor is administered by intravitreal or intravenous administration.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of one of claims 1 to 52, wherein the retinoic acid receptor inhibitor is administered by intravitreal administration.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of one of claims 1 to 52, wherein the vision degeneration is associated with a reduction in cone cells.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of one of claims 1 to 52, wherein the vision degeneration is associated with a reduction in rod cells.
